Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma
Open Access
- 26 November 2018
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 185 (5) , 1002-1004
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK's Haematological Malignancy Research Network (HMRN)British Journal of Haematology, 2018
- Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateauBritish Journal of Haematology, 2016
- The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialHaematologica, 2015
- Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational studyBlood, 2014
- Mantle cell lymphoma epidemiology: a population-based study in FranceAnnals of Hematology, 2014
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013